Photodynamic therapy with 20% 5‑amino‑ketovalerate and 630 nm red light for CIN3
Official title: Efficacy and Safety of Photodynamic Therapy for Cervical Intraepithelial Neoplasia 3(CIN3):A Multicenter Prospective Cohort Study
Run by Peking University Third Hospital · NCT07009327 · Data updated 2026-11-12
This will test whether photodynamic therapy using 20% 5‑amino‑ketovalerate plus 630 nm red light can clear CIN3 lesions in women.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | June 6, 2025 |
| Trial ID | NCT07009327 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women with biopsy‑confirmed CIN3 whose lesions are fully visible in a type 1 or 2 transformation zone and whose ECC does not show high‑grade disease, without porphyria or photosensitivity.
✕Probably not a fit
Patients with suspected or confirmed invasive cancer, glandular/endocervical involvement, TCT HSIL, porphyria or allergy to light, severe medical comorbidities, or lesions that are not fully visible or are in a type 3 transformation zone are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center interventional study at Peking University Third Hospital delivers topical 20% 5‑amino‑ketovalerate followed by 630 nm red‑light activation to treat biopsy-confirmed CIN3 lesions in a real‑world clinical setting. Eligible participants have fully visible lesion boundaries in a type 1 or 2 transformation zone and an ECC that does not indicate high‑grade disease, while those with suspected invasive cancer, glandular involvement, TCT HSIL, porphyria, light allergy, or severe comorbidities are excluded. Investigators will monitor lesion response and safety with colposcopy, cytology, and scheduled follow-up visits, though detailed endpoints and follow-up timing are not provided. The approach aims to test a non‑surgical, fertility‑sparing treatment option and document its tolerability in routine care.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive, fertility‑sparing alternative to excisional surgery for women with CIN3.
How similar studies have gone: Small trials and case series of photodynamic therapy for CIN, including CIN2/3, have reported promising lesion clearance and acceptable safety but large randomized trials remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * CIN3, photodynamic therapy was required, * type 1 2 transformation area, colposcopy was sufficient * the lesion boundary was completely visible * The ECC did not indicate high-grade lesions Exclusion Criteria: * coexistence or suspicion of cancer; * TCT HSIL * involving glands * Porphyria patients, or suspected allergic to red and blue light. * severe medical comorbidities；
Where it's running
-
Peking Unniversity Third Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Qin Han
- Email: Lmlfe_lynn@126.com
- Phone: 13810632686
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using light therapy to treat precancerous cervical and vaginal lesions
This study is testing if light therapy can safely treat precancerous cervical and vaginal lesions in women with specific types of abnormal cells.
-
Evaluating PreveCol for Early Detection of Colorectal Cancer
This study is testing a new blood test called PreveCol to see if it can help find colorectal cancer and advanced polyps in people aged 50-69 who have already had a positive stool test.
-
Investigating the role of extracellular DNA in gastric cancer development
This study is trying to see how changes in a type of DNA found outside of cells might affect the development of gastric cancer in patients with precancerous lesions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.